Chemokines and HIV–1 second receptors
10.1038/nm1296-1293
Crossref journal-article
Springer Science and Business Media LLC
Nature Medicine (297)
Bibliography

D’Souza, M. P., & Harden, V. (1996). Chemokines and HIV–1 second receptors. Nature Medicine, 2(12), 1293–1300.

Authors 2
  1. M. Patricia D'Souza (first)
  2. Victoria Harden (additional)
References 79 Referenced 237
  1. Yoshimura, T.K. & Tanaka, S. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc. Natl. Acad. Sci. USA 84, 9233–9237 (1987). (10.1073/pnas.84.24.9233) / Proc. Natl. Acad. Sci. USA by TK Yoshimura (1987)
  2. Murphy, P.M. The molecular biology of leukocyte chemoattractant receptors. Annu. Rev. Immunol. 12, 593–633 (1994). (10.1146/annurev.iy.12.040194.003113) / Annu. Rev. Immunol. by PM Murphy (1994)
  3. Nussbaum, O., Broder, C.C. & Berger, E.A. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating Cell fusion-dependent reporter gene activation. J. Virol. 68, 5411–5422 (1994). (10.1128/JVI.68.9.5411-5422.1994) / J. Virol. by O Nussbaum (1994)
  4. Litwin, V. et al. Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer. J. Virol. 70, 6437–6441 (1996). (10.1128/JVI.70.9.6437-6441.1996) / J. Virol. by V Litwin (1996)
  5. Connor, R.I., Chen, B.K., Choe, S. & Landau, N.R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206, 936–944 (1995). (10.1006/viro.1995.1016) / Virology by RI Connor (1995)
  6. Helseth, E. et al. Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J. Virol 64, 2416–2420 (1990). (10.1128/JVI.64.5.2416-2420.1990) / J. Virol by E Helseth (1990)
  7. Sullivan, N., Sun, Y., Li, J., Hofmann, W. & Sodroski, J. Replicate function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69, 4413–4422 (1995). (10.1128/JVI.69.7.4413-4422.1995) / J. Virol. by N Sullivan (1995)
  8. Cohen, J. Likely HIV cofactor found. Science 272, 809–810 (1996). (10.1126/science.272.5263.809) / Science by J Cohen (1996)
  9. Walker, C.M., Moody, D.J., Stites, D.P. & Levy, J.A. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234, 1563–1566 (1986). (10.1126/science.2431484) / Science by CM Walker (1986)
  10. Walker, C.M. & Levy, J.A. A diffusable lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. Immunology 66, 628–630 (1989). / Immunology by CM Walker (1989)
  11. Brinchmann, J.E., Gaudernack, G. & Vartdal, F. CD8+ cells inhibit HIV replication in naturally infected CD4+ cells: Evidence for a soluble inhibitor. J Immunol. 144, 2961–2966 (1990). (10.4049/jimmunol.144.8.2961) / J Immunol. by JE Brinchmann (1990)
  12. Mackewicz, C.E., Ortega, H.W. & Levy, J.A. CD8 Cell anti-HIV activity correlates with the clinical state of the infected individual. J. Clin. Invest 87, 1462–1466 (1991). (10.1172/JCI115153) / J. Clin. Invest by CE Mackewicz (1991)
  13. Gomez, A.M., Smaill, P.M. & Rosenthal, K.L. Inhibition of HIV replication by CD8+ T cells correlates with CD4 counts and clinical stage of disease. Clin. Exp. Immunol. 97, 68–75 (1994). (10.1111/j.1365-2249.1994.tb06581.x) / Clin. Exp. Immunol. by AM Gomez (1994)
  14. Cao, Y., Qin, L., Zhang, L., Safrit, J. & Ho, D.D. Virological and immunological characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332, 201–208 (1995). (10.1056/NEJM199501263320401) / N. Engl. J. Med. by Y Cao (1995)
  15. Powell, D.J. et al. Inhibition of cellular activation of retroviral replication by CD8+ T cell derived from non-human primates. Clin. Exp. Immunol. 91, 473–481 (1993). (10.1111/j.1365-2249.1993.tb05927.x) / Clin. Exp. Immunol. by DJ Powell (1993)
  16. Ennen, J. et al. CD8+ T lymphocytes of African Green monkeys secrete an immunodeficiency virus-suppressing lymphokine. Proc. Natl. Acad. Sci. USA 91, 7207–7211 (1994). (10.1073/pnas.91.15.7207) / Proc. Natl. Acad. Sci. USA by J Ennen (1994)
  17. Castro, B.A., Walker, C.M., Eichberg, J.W. & Levy, J.A. Suppression of human immunodeficiency virus replication by CD8+ cells from infected and uninfected chimpanzees. Cell. Immunol. 132, 246–255 (1991). (10.1016/0008-8749(91)90023-5) / Cell. Immunol. by BA Castro (1991)
  18. Mackewicz, C.E., Ortega, H. & Levy, J.A. Effect of cytokines on HIV replication in CD4+ lymphocytes: Lack of identity with the CD8+ cell antiviral factor. Cell. Immunol. 153, 329–343 (1994). (10.1006/cimm.1994.1032) / Cell. Immunol. by CE Mackewicz (1994)
  19. Brinchmann, J.E., Gaudernack, G. & Vartdal, F. In vitro replication of HIV-1 in naturally infected CD4+ T cells is inhibited by rIFN alpha2 and by a soluble factor secreted by activated CD8+ T cells, but not by rIFN beta, rIFN gamma, or recombinant tumor necrosis factor-alpha. J. Acquir. Immune Defic. Syndr. 4, 480–488 (1991). / J. Acquir. Immune Defic. Syndr. by JE Brinchmann (1991)
  20. Cocchi, F. et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270, 1811–1815 (1995). (10.1126/science.270.5243.1811) / Science by F Cocchi (1995)
  21. Moriuchi, H., Moriuchi, M. & Fauci, A.S. CD8+ T cell soluble factor (s), but not chemokines RANTES, MIP-1a, and MIP-1b, can suppress HIV-1 replication in the monocyte/macrophage system. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. Abstracts of the 1996 Annual Meeting of the Institute of Human Virology, 9–13 September 1996, Abstr. 18. (1996). (10.1073/pnas.93.26.15341)
  22. Baier, M., Werner, A., Bannert, N., Metzner, K. & Kurth, R. HIV suppression by interleukin-16. Nature 378, 563 (1995). (10.1038/378563a0) / Nature by M Baier (1995)
  23. Fauci, A.S., Masur, H., Gelmann, E.P., Hahn, B.H. & Lane, H.C. The acquired immunodeficiency syndrome: An update. Ann. Intern. Med. 102, 800–813 (1985). (10.7326/0003-4819-102-6-800) / Ann. Intern. Med. by AS Fauci (1985)
  24. Gartner, S. et al. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233, 215–219 (1996). (10.1126/science.3014648) / Science by S Gartner (1996)
  25. Roos, M.T.L. et al. Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J. Infect. Dis. 165, 427–432 (1992). (10.1093/infdis/165.3.427) / J. Infect. Dis. by MTL Roos (1992)
  26. Schuitemaker, H. et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T cell-tropic populations. J. Virol 66, 1354–1360 (1992). (10.1128/JVI.66.3.1354-1360.1992) / J. Virol by H Schuitemaker (1992)
  27. Conner, R.I. & Ho, D.D. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J. Virol. 68, 4400–4408 (1994). (10.1128/JVI.68.7.4400-4408.1994) / J. Virol. by RI Conner (1994)
  28. Tersmette, M. et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: Frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency virus syndrome (AIDS) and AIDS-related complex. J. Virol 62, 2026–2032 (1988). (10.1128/JVI.62.6.2026-2032.1988) / J. Virol by M Tersmette (1988)
  29. Tersmette, M. et al. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency virus syndrome: Studies on sequential isolates. J Virol 63, 2118–2125 (1989). (10.1128/JVI.63.5.2118-2125.1989) / J Virol by M Tersmette (1989)
  30. Tersmette, M. et al. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1, 983–985 (1989). (10.1016/S0140-6736(89)92628-7) / Lancet by M Tersmette (1989)
  31. Dalgleish, A.G. et al The CD4 (T4) antigen is an essential component of the receptor of the AIDS retrovirus. Nature 312, 763–767 (1984). (10.1038/312763a0) / Nature by AG Dalgleish (1984)
  32. Klatzmann, D. et al T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312, 20–27 (1984). (10.1038/312767a0) / Nature by D Klatzmann (1984)
  33. McDougal, J.S. et al Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. Science 231, 382–385 (1985). (10.1126/science.3001934) / Science by JS McDougal (1985)
  34. Maddon, P.J. et al The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47, 333–348 (1986). (10.1016/0092-8674(86)90590-8) / Cell by PJ Maddon (1986)
  35. Landau, N.R., Warton, M. & Littman, D.R. The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4. Nature 334, 159–162 (1988). (10.1038/334159a0) / Nature by NR Landau (1988)
  36. O'Brien, W.A. etal HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp 120 outside the CD4-binding domain. Nature 348, 69–73 (1990). (10.1038/348069a0) / Nature by WA O'Brien (1990)
  37. Shioda, T., Levy, J.A. & Cheng-Mayer, C. Macrophage and T cell line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 349, 167–169 (1991). (10.1038/349167a0) / Nature by T Shioda (1991)
  38. Hwang, S.S. et al Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253, 71–74 (1991). (10.1126/science.1905842) / Science by SS Hwang (1991)
  39. Skinner, M.A. et al Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J. Virol 62, 4195–4200–(1988). (10.1128/JVI.62.11.4195-4200.1988) / J. Virol by MA Skinner (1988)
  40. Grimaila, R. et al Mutations in the principal neutralizing determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization. J Virol 66, 1875–1883 (1992). (10.1128/JVI.66.4.1875-1883.1992) / J Virol by R Grimaila (1992)
  41. Broder, C.C., Nussbaum, O., Gutheil, W.G., Bachovchin, W.W. & Berger, E.A. CD26 antigen and HIV fusion. Science 264, 1156–1159 (1994). (10.1126/science.7909959) / Science by CC Broder (1994)
  42. Patience, C. et al CD26 antigen and HIV fusion. Science 264, 1159–1160 (1994). (10.1126/science.7909960) / Science by C Patience (1994)
  43. Camerini, D., Planelles, V. & Chen, I.S.Y. CD26 antigen and HIV fusion. Science 264, 1160–1161 (1994). (10.1126/science.7909961) / Science by D Camerini (1994)
  44. Alizon, M. & Dragic, T. CD26 antigen and HIV fusion. Science 264, 1161–1162 (1994). (10.1126/science.7909962) / Science by M Alizon (1994)
  45. Werner, A. et al. CD26 is not required for infection for the lymphoma cell line C8166 with HIV-1. AIDS 8, 1348–1349 (1994). (10.1097/00002030-199409000-00023) / AIDS by A Werner (1994)
  46. West, W.H.L. & Stott, E.J. Cell surface expression of CD26 does not correlate with susceptibility to immunodeficiency viruses. AIDS 8, 1349–1350 (1994). (10.1097/00002030-199409000-00024) / AIDS by WHL West (1994)
  47. Feng, Y., Broder, C.C., Kennedy, P.E. & Berger, E.A. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872–877 (1996). (10.1126/science.272.5263.872) / Science by Y Feng (1996)
  48. Endres, M.J. et al. CD4-independent infection by HIV-2 is mediated by fusin. Cell 87, 745–756 (1996). (10.1016/S0092-8674(00)81393-8) / Cell by MJ Endres (1996)
  49. Federsppiel, B. et al. Molecular cloning of the cDNA and chromosomal localization of the gene for a putative seven-transmembrane segment (7-TMS) receptor isolated from human spleen. Genomics 16, 707–712 (1993). (10.1006/geno.1993.1251) / Genomics by B Federsppiel (1993)
  50. Jazin, E.E. et al. A proposed bovine neuropeptide Y (NPY) receptor cDNA clone, or its human homologue, confers neither NPY binding sites nor NPY responsiveness on transfected cells. Regul. Pept 47, 247–258 (1993). (10.1016/0167-0115(93)90392-L) / Regul. Pept by EE Jazin (1993)
  51. Loetscher, M. et al. Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J. Biol Chem. 269, 232–237 (1994). (10.1016/S0021-9258(17)42339-8) / J. Biol Chem. by M Loetscher (1994)
  52. Bleul, C.C. et al The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382, 829–832 (1996). (10.1038/382829a0) / Nature by CC Bleul (1996)
  53. Oberlin, E. et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382, 833–835 (1996). (10.1038/382833a0) / Nature by E Oberlin (1996)
  54. Bleul, C.C., Fuhlbrigge, R.C., Casanovas, J.M., Aiuti, A. & Springer, T. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J. Exp. Med. 184, 1101–1109 (1996). (10.1084/jem.184.3.1101) / J. Exp. Med. by CC Bleul (1996)
  55. Nagasawa, T. et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382, 635–638 (1996). (10.1038/382635a0) / Nature by T Nagasawa (1996)
  56. Samson, M., Labbe, O., Mollereau, C., Vassart, G. & Parmentier, M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 35, 3362–3367 (1996). (10.1021/bi952950g) / Biochemistry by M Samson (1996)
  57. Dragic, T. et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CD-CKR-5. Nature 381, 667–673 (1996). (10.1038/381667a0) / Nature by T Dragic (1996)
  58. Deng, H. et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661–667 (1996). (10.1038/381661a0) / Nature by H Deng (1996)
  59. Alkhatib, G. et al. CC CKR5: A RANTES, MIP-lα, MIP-lβ receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955–1958 (1996). (10.1126/science.272.5270.1955) / Science by G Alkhatib (1996)
  60. Doranz, B.J. et al. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85, 1149–1158 (1996). (10.1016/S0092-8674(00)81314-8) / Cell by BJ Doranz (1996)
  61. Hyeryun, C. et al. The b-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85, 1135–1148 (1996). (10.1016/S0092-8674(00)81313-6) / Cell by C Hyeryun (1996)
  62. Combadiere, C., Ahuja, S.K. & Murphy, P.M. Cloning and functional expression of a human eosinophil CC chemokine receptor. J. Biol. Chem. 270, 16491–16494 (1995). (Correction, J. Biol Chem. 270; 30235). (10.1074/jbc.270.28.16491) / J. Biol. Chem. by C Combadiere (1995)
  63. Berson, J.F. et al. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J. Virol. 70, 6288–6295 (1996). (10.1128/JVI.70.9.6288-6295.1996) / J. Virol. by JF Berson (1996)
  64. Collman, R. et al. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J. Virol. 66, 7517–7521 (1992). (10.1128/JVI.66.12.7517-7521.1992) / J. Virol. by R Collman (1992)
  65. Lapham, C.K. et al. Evidence for cell-surface association between fusin and the CD4-gpl20 complex in human cell lines. Science 274, 602–605 (1996). (10.1126/science.274.5287.602) / Science by CK Lapham (1996)
  66. Wu, L. et al CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR5. Nature 384, 179–183 (1996). (10.1038/384179a0) / Nature by L Wu (1996)
  67. Trkola, A. et al. CD4-dependent, neutralizing antibody-sensitive interactions between HIV-1 gp120 and the CCR-5 CC-chemokine receptor. Nature 384, 184–187 (1996). (10.1038/384184a0) / Nature by A Trkola (1996)
  68. Cocchi, F. et al The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nature Med. 2, 1244–1247 (1996). (10.1038/nm1196-1244) / Nature Med. by F Cocchi (1996)
  69. Paxton, W.A. et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nature Med. 2, 412–417 (1996). (10.1038/nm0496-412) / Nature Med. by WA Paxton (1996)
  70. Liu, R. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed Individuals to HIV-1 Infection. Cell 86, 367–377 (1996). (10.1016/S0092-8674(00)80110-5) / Cell by R Liu (1996)
  71. Samson, M. et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 382, 722–725 (1996). (10.1038/382722a0) / Nature. by M Samson (1996)
  72. Dean, M. et al. Genetic restriction of HIV-1 infection and progression to AIDS by a detection allele of the CKR5 structural gene. Science 273, 1856–1862 (1996). (10.1126/science.273.5283.1856) / Science by M Dean (1996)
  73. Huang, Y. et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med. 2, 1240–1243 (1996). (10.1038/nm1196-1240) / Nature Med. by Y Huang (1996)
  74. Rowland-Jones, S. et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Med. 1, 59–64 (1995). (10.1038/nm0195-59) / Nature Med. by S Rowland-Jones (1995)
  75. Horuk, R. et al. A receptor for the malarial parasite Plasmodium vivax: The ery-throcyte chemokine receptor. Science 261, 1182–1184 (1993). (10.1126/science.7689250) / Science by R Horuk (1993)
  76. Munoz, A. et al. Long-term survivors with HIV-1 Infection: Incubation period and longitudinal patterns of CD4+ lymphocytes. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8, 496–505 (1994). (10.1097/00042560-199504120-00010) / J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. by A Munoz (1994)
  77. Wild, C., Greenwell, T., Shugars, D., Rimsky-Clarke, L. & Matthews, T. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res. Hum. Retroviruses 11, 323–325 (1995). (10.1089/aid.1995.11.323) / AIDS Res. Hum. Retroviruses by C Wild (1995)
  78. Arenzana-Seisdedos, F. et al. HIV blocked by chemokine antagonist. Nature 383, 400 (1996). (10.1038/383400a0) / Nature by F Arenzana-Seisdedos (1996)
  79. Schmidtmayerova, H., Sherry, B. & Bukrinsky, M. Chemokines and HIV replication. Nature 382, 767 (1996). (10.1038/382767a0) / Nature by H Schmidtmayerova (1996)
Dates
Type When
Created 21 years ago (Aug. 18, 2004, 9:22 p.m.)
Deposited 2 years, 3 months ago (May 18, 2023, 6:23 p.m.)
Indexed 4 months, 1 week ago (April 11, 2025, 4:48 a.m.)
Issued 28 years, 8 months ago (Dec. 1, 1996)
Published 28 years, 8 months ago (Dec. 1, 1996)
Published Print 28 years, 8 months ago (Dec. 1, 1996)
Funders 0

None

@article{D_Souza_1996, title={Chemokines and HIV–1 second receptors}, volume={2}, ISSN={1546-170X}, url={http://dx.doi.org/10.1038/nm1296-1293}, DOI={10.1038/nm1296-1293}, number={12}, journal={Nature Medicine}, publisher={Springer Science and Business Media LLC}, author={D’Souza, M. Patricia and Harden, Victoria}, year={1996}, month=dec, pages={1293–1300} }